Literature DB >> 21925170

GADD34 mediates cytoprotective autophagy in mutant huntingtin expressing cells via the mTOR pathway.

Alise Hyrskyluoto1, Sami Reijonen, Jenny Kivinen, Dan Lindholm, Laura Korhonen.   

Abstract

Increased protein aggregation and altered cell signaling accompany many neurodegenerative diseases including Huntington's disease (HD). Cell stress is counterbalanced by signals mediating cell repair but the identity of these are not fully understood. We show here that the mammalian target of rapamycin (mTOR) pathway is inhibited and cytoprotective autophagy is activated in neuronal PC6.3 cells at 24 h after expression of mutant huntingtin proteins. Tuberous sclerosis complex (TSC) 1/2 interacted with growth arrest and DNA damage protein 34 (GADD34), which caused TSC2 dephosphorylation and induction of autophagy in mutant huntingtin expressing cells. However, GADD34 and autophagy decreased at later time points, after 48 h of transfection with the concomitant increase in mTOR activity. Overexpression of GADD34 counteracted these effects and increased cytoprotective autophagy and cell survival. These results show that GADD34 plays an important role in cell protection in mutant huntingtin expressing cells. Modulation of GADD34 and the TSC pathway may prove useful in counteracting cell degeneration accompanying HD and other neurodegenerative diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925170     DOI: 10.1016/j.yexcr.2011.08.020

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  24 in total

1.  A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Future Neurol       Date:  2012-11

Review 2.  Mapping the crossroads of immune activation and cellular stress response pathways.

Authors:  Nuno Cláudio; Alexandre Dalet; Evelina Gatti; Philippe Pierre
Journal:  EMBO J       Date:  2013-04-12       Impact factor: 11.598

3.  Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.

Authors:  Hiroshi Nakashima; Tran Nguyen; Kazue Kasai; Carmela Passaro; Hirotaka Ito; William F Goins; Imran Shaikh; Ronald Erdelyi; Reiko Nishihara; Ichiro Nakano; David A Reardon; Ana C Anderson; Vijay Kuchroo; E Antonio Chiocca
Journal:  Clin Cancer Res       Date:  2018-03-06       Impact factor: 12.531

Review 4.  The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Biochem Soc Trans       Date:  2018-03-09       Impact factor: 5.407

Review 5.  Cutting through the complexities of mTOR for the treatment of stroke.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2014-05       Impact factor: 1.990

Review 6.  Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2017       Impact factor: 1.990

Review 7.  Novel directions for diabetes mellitus drug discovery.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang
Journal:  Expert Opin Drug Discov       Date:  2012-10-24       Impact factor: 6.098

Review 8.  Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2018       Impact factor: 1.990

Review 9.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Prog Neurobiol       Date:  2012-08-15       Impact factor: 11.685

Review 10.  Taking aim at Alzheimer's disease through the mammalian target of rapamycin.

Authors:  Kenneth Maiese
Journal:  Ann Med       Date:  2014-08-08       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.